Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Infinity, thanks for comments. Some clarifications:

Slide 12, right graph is for 200 mg PP group of 20 total subject. 65 % or 13 them were IGA 3. This is the group IPIX refers to in the press release: 46.2 % experiencing at least 2 point drop. That 46.2 % gives 6 subjects. 7 out of 27 refers to all responders in ITT and includes original IGA 2 and IGA 3 subjects.

ITT numbers I used come from the table in slide 9. It says for 200 mg group that 9 were IGA 2, 18 IGA 3 and 1 subject with missing baseline value. You have a choice of two baseline values for 200 mg IGA 3, 18 without the missing subject or 19 with the missing included. Totals for 2+ point drops are from the table in slide 10.

Percentages for 2+ IGA point drop for 200 MG IGA 3 Group, PASI 75 percentage probably the same or a bit better
6/18 --> 33.3 %
6/19 --> 31.6 %

Making investment choices based on results from small is risky, very risky. I don't deny that. But small P2 trials are a fact of life with almost all small biotechs. Don't make IPIX sound like an exception.

Anyway, I rather risk my money based on good results from a small trial than on bad results from the same trial. There is a difference.